5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats. 1995

B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
Department of Psychiatry, University of Alberta, Edmonton, Canada.

The effects of 5-HT3 receptor antagonists (ondansetron 0.1 mg kg-1 SC 30 min; bemesetron 0.03 mg kg-1 SC 45 min) on nicotine-induced increases in locomotor activity were measured in male Sprague-Dawley rats. Intermittent daily injections of nicotine (0.3-1.2 mg kg-1 SC 30 min) resulted in increased locomotor activity as measured by photocell counts. The effect of nicotine was not affected by administration of the 5-HT3 receptor antagonists at doses that are reported to block nicotine- and morphine-induced place-preference conditioning. Neither of the 5-HT3 receptor antagonists tested affected activity counts in vehicle treated animals. Nicotine-induced hyperactivity was blocked by the dopamine antagonist haloperidol (0.03 mg kg-1 SC 2 h) and by the nicotinic antagonist mecamylamine (1 mg kg-1 SC 1 min). The effects of a range of doses (0-1 mg kg-1) of the 5-HT3 receptor antagonists ondansetron, bemesetron, granisetron and tropisetron on hyperactivity induced by 0.6 mg kg-1 nicotine were then assessed. Only tropisetron at 1 mg kg-1 attenuated nicotine-induced hyperactivity. To demonstrate the efficacy of the present range of doses of the 5-HT3 receptor antagonists in this study, conditioned taste aversion experiments were conducted. Ondansetron (0.1 mg kg-1) failed to attenuate a conditioned taste aversion to saccharin induced by nicotine (0.6 mg kg-1), but did induce a reduction in saccharin preference in choice tests following three saccharin-ondansetron pairings.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000077526 Tropisetron An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting. (3 alpha-Tropanyl)-1H-indole-3-carboxylic Acid Ester,ICS 205-930,ICS-205-930,ICS-205930,Indole-3-carboxylic Acid Tropine Ester,Navoban,Tropisetron Hydrochloride,ICS 205 930,ICS 205930,Indole 3 carboxylic Acid Tropine Ester
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin

Related Publications

B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
January 1989, Psychopharmacology,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
May 1997, European journal of pharmacology,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
August 1988, European journal of pharmacology,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
August 2005, Drug and therapeutics bulletin,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
October 1982, Pharmacology, biochemistry, and behavior,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
May 2004, Biochemical and biophysical research communications,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
May 1996, Epilepsy research,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
June 1988, European journal of pharmacology,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
April 2004, Behavioral neuroscience,
B Arnold, and K Allison, and S Ivanová, and P R Paetsch, and T Paslawski, and A J Greenshaw
November 2003, Psychopharmacology,
Copied contents to your clipboard!